sgRNA amount is a limiting factor in adenine base editing using RNA LNPs
Open Access
- 18 March 2026
- journal article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (2) , 102909
Abstract
No abstract availableKeywords
Funding Information
- NanoMedicines Innovation Network (2019-T2-05)
- Genome British Columbia (SIP005)
- Canadian Institutes of Health Research
- Michael Smith Health Research BC (16458)
This publication has 33 references indexed in Scilit:
- Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA DeliverySmall, 2024
- Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain DiseaseACS Nano, 2023
- Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissuesMolecular Therapy - Methods & Clinical Development, 2023
- Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal MusclesACS Applied Materials & Interfaces, 2023
- A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editorsMolecular Therapy, 2023
- LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse corneaJournal of Controlled Release, 2022
- A precise and efficient adenine base editorMolecular Therapy, 2022
- Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiencyMolecular Therapy, 2022
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome EditingCell Reports, 2018
- COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target SitesMolecular Therapy Nucleic Acids, 2014